Impact of CYP2D6 inhibitors on tamoxifen metabolism in breast cancer patients

被引：0
|
作者：
Keller, Denise [1 ]
Medwid, Samantha [2 ]
Schwarz, Ute [2 ]
Legan, Robin [1 ]
Kim, Richard [2 ]
机构：
[1] London Hlth Sci Ctr, London, ON, Canada
[2] Univ Western Ontario, London, ON, Canada
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2023年 / 180卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P0065
引用
收藏
页码：250 / 253
页数：4
相关论文
共 50 条
  • [1] Impact of the CYP2D6 phenotype on the outcome of breast cancer patients treated with tamoxifen
    Dorado, Pedro
    Penas-Lledo, Eva
    LLerena, Adrian
    PHARMACOGENOMICS, 2013, 14 (06) : 606 - 606
  • [2] The Impact of CYP2D6*4 on the Survival of Tamoxifen Treated Breast Cancer Patients
    Al Matrafi, Abdullah
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 1345 - 1346
  • [3] Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
    T. Ramón y Cajal
    A. Altés
    L. Paré
    E. del Rio
    C. Alonso
    A. Barnadas
    M. Baiget
    Breast Cancer Research and Treatment, 2010, 119 : 33 - 38
  • [4] Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
    Ramon y Cajal, T.
    Altes, A.
    Pare, L.
    del Rio, E.
    Alonso, C.
    Barnadas, A.
    Baiget, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 33 - 38
  • [5] Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
    Borges, Silvana
    Desta, Zeruesenay
    Li, Lang
    Skaar, Todd C.
    Ward, Bryan A.
    Nguyen, Anne
    Jin, Yan
    Storniolo, Anna Maria
    Nikoloff, D. Michele
    Wu, Lin
    Hillman, Grant
    Hayes, Daniel F.
    Stearns, Vered
    Flockhart, David A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) : 61 - 74
  • [6] Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors
    Aubert, R. E.
    Stanek, E. J.
    Yao, J.
    Teagarden, J. R.
    Subar, M.
    Epstein, R. S.
    Skaar, T. C.
    Desta, Z.
    Flockhart, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [7] Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
    Laurent Azoulay
    Sophie Dell’Aniello
    Laetitia Huiart
    Guillaume Galbaud du Fort
    Samy Suissa
    Breast Cancer Research and Treatment, 2011, 126 : 695 - 703
  • [8] Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
    Azoulay, Laurent
    Dell'Aniello, Sophie
    Huiart, Laetitia
    du Fort, Guillaume Galbaud
    Suissa, Samy
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (03) : 695 - 703
  • [9] Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen
    Ferraldeschi, Roberta
    Howell, Sacha J.
    Thompson, Alastair M.
    Newman, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : E584 - E585
  • [10] Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
    Schroth, Werner
    Winter, Stefan
    Muerdter, Thomas
    Schaeffeler, Elke
    Eccles, Diana
    Eccles, Bryony
    Chowbay, Balram
    Khor, Chiea C.
    Tfayli, Arafat
    Zgheib, Nathalie K.
    Eichelbaum, Michel
    Schwab, Matthias
    Brauch, Hiltrud
    FRONTIERS IN PHARMACOLOGY, 2017, 8
12345